← Back to Clinical Trials
Recruiting NCT07546539

NCT07546539 Photobiomodulation in Chronic Fatigue Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07546539
Status Recruiting
Phase
Sponsor University of Lahore
Condition Chronic Fatigue Syndrome (CFS)
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-06-15
Primary Completion 2026-07-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Photobiomodulation (Low-Level Laser Therapy)sham Photobiomodulation (LLLT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-06-15 with a primary completion date of 2026-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 years diagnosed with chronic fatigue syndrome. The main questions it aims to answer are: Does photobiomodulation therapy significantly reduce fatigue levels as measured by the Fatigue Severity Scale (FSS) and Multidimensional Fatigue Inventory (MFI-20)? Does photobiomodulation therapy improve pain, functional capacity, sleep quality, and psychological well-being in patients with chronic fatigue syndrome? Researchers will compare the low-level laser therapy group with a placebo (sham laser) group to determine whether photobiomodulation therapy leads to greater improvements in fatigue, pain, and overall quality of life. Participants will: Receive either active low-level laser therapy or placebo treatment three times per week for eight weeks Undergo assessments of fatigue, pain, functional capacity, quality of life, sleep quality, and psychological well-being at baseline and follow-up intervals (3, 6, and 12 months)

Eligibility Criteria

Inclusion Criteria * Age 18-60 years * Diagnosis of a CFS according to the 2015 Institute of Medicine criteria * Fatigue Severity Scale (FSS) score ≥ 4 * Ability to understand study procedures and provide informed consent Exclusion Criteria * Comorbid psychiatric conditions (e.g., major depression, schizophrenia) * Current use of corticosteroids or immunomodulators * Known photosensitivity or dermatologic contraindications to LLLT * Participation in structured exercise programs more than twice weekly * Diagnosed malignancy or active infection -Not willing to be the part of study -

Contact & Investigator

Central Contact

Dr Adil Amir Ali Dr Aadil Amir Ali, PhD

✉ aadilamirali@hotmail.com

📞 923002929464

Frequently Asked Questions

Who can join the NCT07546539 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Chronic Fatigue Syndrome (CFS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07546539 currently recruiting?

Yes, NCT07546539 is actively recruiting participants. Contact the research team at aadilamirali@hotmail.com for enrollment information.

Where is the NCT07546539 trial being conducted?

This trial is being conducted at Larkana, Pakistan.

Who is sponsoring the NCT07546539 clinical trial?

NCT07546539 is sponsored by University of Lahore. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology